Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 691 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Corticosteroid Clear all

Conditions: Chronic Graft Versus Host Disease
Interventions: Belumosudil, Placebo, Prednisone, Prednisolone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 24
States / cities: Little Rock, Arkansas • Duarte, California • San Francisco, California + 21 more

Conditions: Adrenocortical Carcinoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma
Interventions: No intervention; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hemangioma
Interventions: Prednisolone; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 6 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Primary Immune Thrombocytopenia (ITP)
Interventions: Ianalumab, Placebo, Corticosteroids; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 20
States / cities: Yuma, Arizona • Clovis, California • Fountain Valley, California + 16 more

Conditions: Asthma
Interventions: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler, Placebo inhalation powders via ELLIPTA inhaler, Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler, Placebo inhalation powder via ACCUHALER/DISKUS inhaler, Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 34
States / cities: Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more

Conditions: Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Kidney Cancer, Liver Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Sarcoma
Interventions: colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study, conventional surgery; Biological · Other · Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Post-surgical Ocular Inflammation, Post-surgical Ocular Pain
Interventions: SURF-201, Placebo; Drug
Lead sponsor: Surface Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 10
States / cities: Hemet, California • Murrieta, California • Brooksville, Florida + 7 more

Conditions: Neoplasms, Heart Diseases, Adrenal Cortex Diseases
Interventions: Case management; Behavioral
Lead sponsor: Metropolitan Jewish Health System; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Ulcerative Colitis
Interventions: ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, Placebo; Drug
Lead sponsor: Abivax S.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: San Diego, California • Decatur, Georgia • Austin, Texas + 1 more

Conditions: Healthy
Interventions: PMI-150 (intranasal ketamine HCl); mometasone furoate; Drug
Lead sponsor: Javelin Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Renal Cell Carcinoma, Melanoma, Lung Cancer
Interventions: Infliximab + Prednisone, Methylprednisolone + Prednisone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone and salmeterol; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma
Interventions: lebrikizumab, placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 70
States / cities: Pell City, Alabama • Scottsdale, Arizona • Tucson, Arizona + 63 more

Conditions: Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions: Extracorporeal Photopheresis (ECP), Methoxsalen; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Uveitis
Interventions: B27PD, Placebo; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperaldosteronism
Interventions: Not listed
Lead sponsor: University Hospital Padova; Other
Eligibility: 18 Years and older
Enrollment: 2,604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Dallas, Texas • Menomonee Falls, Wisconsin

Conditions: Orthostatic Hypotension, Hemodynamic Instability, Fever, Hypothermia
Interventions: Hydrocortisone High Dose, Hydrocortisone Low Dose; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Femoroacetabular Impingement
Interventions: platelet-rich plasma injection, Kenalog 10 MG/ML Injectable Suspension; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 45 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, VI, UMEC, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 11 more

Conditions: Asthma
Interventions: Tezepelumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Mobile, Alabama • Gilbert, Arizona • Long Beach, California + 34 more

Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions: LY3650150, Placebo, Standard therapy for INCS; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more

Conditions: Cutaneous Lupus
Interventions: 532nm laser, 1064nm laser, Topical corticosteroid; Device · Drug
Lead sponsor: David Weinstein; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Asthma
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 65
States / cities: Bakersfield, California • Huntington Beach, California • La Mesa, California + 61 more

Search by objective public record fields.

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma

Study to Evaluate the Impact of Obesity on Airway Inflammation and Mechanics in Asthmatics

Immune Suppression Of Infants Treated With Steroids

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects

The Effects of Case Management in a Medicaid Managed Care Plan

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis

Adrenal Vein Sampling International Study (AVIS Study)

Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery

Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids